# Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

> **NCT03820141** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 51 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT03820141
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-30
- **Primary completion:** 2024-10-30
- **Final completion:** 2028-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03820141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03820141, "Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03820141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*